



LEERINK SWANN

Robert Dreicer MD MS FACP

Dr Dreicer is Chair of the Department of Solid Tumor Oncology at the Taussig Cancer Institute at the Cleveland Clinic as well as a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine in Cleveland, OH. In addition, he is the Director of the Genitourinary Medical Oncology Program and Associate Director of Experimental Therapeutics at the Taussig Cancer Institute. Dr Dreicer's major professional interests focus on the management of genitourinary malignancies and on clinical trials for novel agents for the treatment of these conditions. In 2008, Dr Dreicer was the Chairman of the Steering Committee for the American Society of Clinical Oncology (ASCO) GU Cancer Symposium. He is currently the Chair of the Bladder Cancer Subcommittee of the Eastern Cooperative Oncology Group (ECOG), and on the GU Core Committee of ECOG. Dr Dreicer has published widely on the management of kidney, prostate, bladder, and testicular cancers. He is an associate editor of *Urology* and on the editorial boards of the *Journal of Clinical Oncology*, *Clinical Genitourinary Cancer*, and the *Journal of Supportive Oncology*.

Francine Foss MD

Dr Foss is a Professor of Internal Medicine specializing in Medical Oncology with a secondary appointment in Dermatology at Yale University Comprehensive Cancer Center in New Haven, CT. Additionally, she is Assistant Director of Clinical Investigation of Hematological Malignancies at Yale. Dr Foss is focused on finding novel treatments for primary cutaneous lymphoma, especially cutaneous T-cell lymphoma (CTCL) and stem cell allotransplantation. She is also currently involved with clinical studies for ovarian cancer, graft-vs-host disease, and skin cancer. She has designed, initiated, and directed multi-center national clinical trials of two pharmacologic agents for lymphoma, which have subsequently received FDA approval and are widely used treatments. One of these, Ontak (Interleukin-2 conjugated to Diphtheria toxin, EASLY), was the first FDA approved fusion biologic drug to be approved for use in the United States. Dr Foss introduced the idea of intravenous infusions of autologous immature dendritic cells before an allogeneic bone marrow transplant, which has reduced the development of graft-versus-host disease in patients from the average of 40-50 percent to only 15 percent. These findings, initially revealed through a study of 104 lymphoma patients in her care, have been confirmed through a national Phase II trial. Dr. Foss chaired the plenary session on T-Cell Lymphoma at the last two International Meetings on Lymphoma and has been an invited speaker at over 40 national and international conferences and annual meetings over the last three years.

Vince Miller MD

Dr Miller is an Associate Attending Physician and member of the Thoracic Oncology Service in the Department of Medicine at Memorial Sloan-Kettering Cancer Center and an Associate Professor of Medicine at Weill Medical College of Cornell University in New York City. His main research focus is on the treatment of non-small cell lung carcinoma (NSCLC). Dr. Miller has been a leader in the development of therapies targeted at the HER family of receptors and has a particular interest in the use of these agents in bronchioloalveolar cell carcinoma. Dr Miller has received both the prestigious American Cancer Society Clinical Oncology Career Development Award and the Louise and Allston Boyer Award. Dr. Miller is a Fellow of the American College of Physicians and a Member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer.

Neal Rosen MD, PhD

Dr Rosen is a member of the Department of Medicine and the Molecular Pharmacology and Chemistry Program at Memorial Sloan-Kettering Cancer Center in New York, where he serves as

Head of Developmental Therapeutics. He is also a Professor of Pharmacology, Cell Biology, and Medicine at Cornell University Medical School. His major interests are the identification and study of key molecular events and growth signaling pathways responsible for the development of human cancer and the use of this information for developing mechanism-based therapeutic strategies. Dr Rosen has played an important role in the development of tyrosine kinase-mediated signaling inhibitors and has pioneered the concept that cancer cells are dependent on cellular machinery for protein folding. Multiple novel clinical trials based on the work of the Rosen Laboratory are being tested at Memorial Sloan-Kettering and other cancer centers in the United States and internationally. He was on the senior staff of the Medicine Branch at the National Cancer Institute (NCI) prior to joining the faculty of Memorial Sloan-Kettering Cancer Center.

David Vesole MD PhD FACP

Dr Vesole is a hematology expert in the Multiple Myeloma and Blood Stem Cell Transplant Program at St. Vincent's Comprehensive Cancer Center in New York City (SVCCC). The Multiple Myeloma Program at SVCCC is one of the leading programs in the country for the diagnosis and treatment of multiple myeloma. Dr. Vesole's research focuses on blood and marrow transplantation for hematologic diseases, the diagnosis and treatment of multiple myeloma, and on post-transplant immunotherapy for multiple myeloma. Dr Vesole is the former Co-Chair of the Eastern Cooperative Oncology Group (ECOG) Myeloma Committee and Co-Chair of the Center for International Blood and Marrow Transplant Research (CIBMTR) Plasma Cell Disorder Committee. He serves on the Board of Directors for the New York City Affiliate of the Leukemia & Lymphoma Society, on the Blood and Marrow Transplant Clinical Trials Network Multiple Myeloma Protocol Committee, and is a member of the Scientific Advisory Committee for the International Myeloma Foundation.